Exploring new therapies for COVID-19: focus on a long-acting antibody combination (AZD7442)

Exploring new therapies for COVID-19: focus on a long-acting antibody combination (AZD7442)

Monday, November 2, 2020 1:00 PM to 1:20 PM · 20 min. (Africa/Abidjan)

European Antibody Congress

Antibody therapeutics for COVID-19

Presentation

Information

Mark Esser, Vice President, AstraZeneca

Bio-RadBio-Rad is an expert manufacturer of antibodies, supporting drug discovery and development. Using a library of 45 billion antibodies coupled with innovative phage display technology, we generate customized recombinant monoclonal antibodies for your proof-of-concept target discovery and anti-idiotypic antibodies for bioanalysis. We help you reach your goals by providing the antibodies you need and a professional, long-term partnership for success.

Log in

See all the content and easy-to-use features by logging in